Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
do not add cannabis to the treatment plan.What Better Evidence Would NeedStronger research would follow patients over time with repeated dosing, track mood and psychosis outcomes alongside cognition, and test whether the acute timing effect persists or fades with regular use.It would also need to identify which patients, if any, show a genuine cognitive benefit versus those for whom cannabis use carries more risk than benefit.Lens takeawayLongitudinal, safety-inclusive research is the next necessary step.Nuance Belongs in Public MessagingPublic and patient-facing messaging about cannabis and bipolar disorder should reflect that this is an early, mixed-design signal, not an endorsement of cannabis as a cognitive treatment.Overstating this finding risks encouraging unsupervised use in a population that already carries elevated risk from cannabis-related mood and psychotic symptoms.Lens takeawayHonest uncertainty protects patients better than an oversimplified headline
Access this article Similar content being viewed by others References Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR, et al
compounding pharmacies that comply with state and federal pharmacy regulations
03 Tell Your Doctor You are pregnant, breastfeeding, or plan to become either
This can help you make informed decisions about your diet and lifestyle
US$ 23.56
US$ 27.17
US$ 20.95
US$ 27.89
